Novo Nordisk's Oral Wegovy Marks a New Frontier, but Cyber Attack and Steep Losses Test Investor Patience
13.06.2026 - 15:18:53 | boerse-global.de
Novo Nordisk’s shares have weathered a turbulent period that encapsulates both the promise and peril facing the Danish pharma giant. The stock closed Friday at €38.03, barely budging from the prior session, though it managed a modest weekly gain of about 2%. That meager advance does little to mask a brutal 12-month slide of nearly 46% from the 52-week high of €70.13, a rout that has slashed billions from its market value.
A Pill Milestone Arrives Amid Digital Intrigue
The company notched a historic regulatory win on June 11 when the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved the oral formulation of Wegovy. It marks the first time a GLP-1 medication in pill form has received the green light for weight loss in Europe, flinging open a new market door. The OASIS-4 trial data underpinning the approval showed an average weight reduction of 16.6% over 64 weeks – a result that strengthens Novo Nordisk’s case that a daily tablet can compete with injections. In Britain alone, 55,000 people sit on waiting lists at private providers, suggesting pent-up demand that could quickly absorb supply.
Yet the triumph was short-lived. The very next day, the company disclosed a cyber attack in which attackers infiltrated internal IT systems and exfiltrated pseudonymised patient data from clinical trials, including biomarkers, lifestyle factors, and participant IDs. More troubling, contact details of doctors and nursing staff – WhatsApp numbers and registration codes among them – were also stolen. Novo Nordisk insists the incident has not disrupted operations and that direct patient identification is unlikely. Under Europe’s GDPR regime, however, the breach invites regulatory scrutiny, and the damage to trust may prove more corrosive. Clinical trial recruitment – the lifeblood of any pipeline-driven pharma – could become harder if participants fear their data is not secure.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Competitive Pressures from All Sides
Even as Novo Nordisk leads with its oral GLP-1 advance, rivals are closing in. Eli Lilly is pushing ahead with its own oral candidate, Foundayo, and at a recent diabetes congress presented strong data for Retatrutide, a triple-hormone agonist that raises the efficacy bar for Novo’s existing portfolio. Pfizer, too, has re-emerged with fresh clinical data. The cozy duopoly that for years sustained fat margins for both Lilly and Novo Nordisk is showing cracks. The market has priced in that risk: the stock has shed roughly 15% since the start of the year alone.
On the operational front, Novo Nordisk is investing €432 million to expand its facility in Athlone, Ireland, which will serve as a hub for oral GLP-1 therapies outside the US. The company expects to have a reliable supply of semaglutide by the third quarter. But supply constraints alone no longer suffice as a bullish narrative. Investors are demanding proof of sustained growth and pricing power.
Technical Battle and the Medicare Catalyst
Technically, the stock shows tentative signs of life. It now trades roughly 4.5% above its 50-day moving average of €36.38, a short-term bullish signal. The path higher, though, is blocked by the 200-day average at €41.43 – a level the shares have not reclaimed since their precipitous fall. The relative strength index sits at 53, indicating neutral territory with no overbought or oversold extremes. The March low of €30.25 likely marks a floor, but calling a durable trend reversal remains premature.
A key test arrives on July 1, when the expansion of the US Medicare programme takes effect. If Novo Nordisk can capture incremental demand from older Americans, the stock could begin to claw back toward that key moving average. Until then, the narrative remains bifurcated: the oral Wegovy approval validates the pipeline and opens a vastly larger addressable market, but the cyber attack, combined with intensifying rivalry from Lilly and Pfizer, leaves the equity in a precarious equilibrium. For now, the bears retain the upper hand until the 200-day line is recaptured.
Ad
Novo Nordisk Stock: New Analysis - 13 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
